Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination in Children with Hematologic Malignancies or Solid Tumors
NCT03373656Unknown
- Sponsor
- Children's Oncology Group
- Start
- May 2017
- Primary completion
- Jul 2025
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Open-label trial of Hepatitis B vaccine and measles vaccine, live attenuated + rubella vaccine, live attenuated in hepatitis B (HBV), measles and rubella (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Number of parents of children willing to be vaccinated after receiving relevant knowledge propagation at 2 years, Number of participants with vaccination-related adverse events at 2 years and 1 more. Status: unknown.
02
Drugs
Hepatitis B vaccinemeasles vaccine, live attenuated + rubella vaccine, live attenuated
03
Conditions
hepatitis B (HBV)measlesrubella
Beyond the preview
Go deeper on NCT03373656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373656.